NovoCure (NVCR) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

NVCR Stock Forecast

NovoCure stock forecast is as follows: an average price target of $30.00 (represents a -0.27% downside from NVCR’s last price of $30.08) and a rating consensus of 'Hold', based on 6 wall street analysts offering a 1-year stock forecast.

NVCR Price Target

The average price target for NovoCure (NVCR) is $30.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $30.00. This represents a potential -0.27% downside from NVCR's last price of $30.08.

NVCR Analyst Ratings

Hold

According to 6 Wall Street analysts, NovoCure's rating consensus is 'Hold'. The analyst rating breakdown for NVCR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (33.33%), 3 'Hold' (50.00%), 1 'Sell' (16.67%), and 0 'Strong Sell' (0.00%).

NovoCure Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 02, 2024	Vijay Kumar	Evercore ISI	$30.00	$26.43	13.53%	-0.27%
Oct 16, 2024	Emily Bodnar	H.C. Wainwright	$30.00	$17.78	68.73%	-0.27%
Jul 26, 2024	Emily Bodnar	H.C. Wainwright	$24.00	$18.25	31.47%	-20.21%
May 03, 2024	Emily Bodnar	H.C. Wainwright	$22.00	$14.19	55.04%	-26.86%
May 02, 2024	Vijay Kumar	Evercore ISI	$14.50	$14.78	-1.89%	-51.80%
Apr 10, 2024	Jason Bednar	Piper Sandler	$28.00	$14.88	88.17%	-6.91%
Apr 03, 2024	Larry Biegelsen	Wells Fargo	$42.00	$14.39	191.87%	39.63%
Mar 27, 2024		H.C. Wainwright	$24.00	$14.64	63.93%	-20.21%
Jan 06, 2023		J.P. Morgan	$99.00	$109.04	-9.21%	229.12%
Jan 06, 2023		Wells Fargo	$107.00	$118.81	-9.94%	255.72%
Jan 05, 2023	Emily Bodnar	H.C. Wainwright	$140.00	$107.44	30.31%	365.43%
Nov 29, 2022		Wells Fargo	$89.00	$70.06	27.03%	195.88%
May 16, 2022	Emily Bodnar	H.C. Wainwright	$115.00	$65.24	76.27%	282.31%
Feb 08, 2022	Jason Wittes	Loop Capital Markets	$200.00	$75.30	165.60%	564.89%

The latest NovoCure stock forecast, released on Dec 02, 2024 by Vijay Kumar from Evercore ISI, set a price target of $30.00, which represents a 13.53% increase from the stock price at the time of the forecast ($26.43), and a -0.27% decrease from NVCR last price ($30.08).

NovoCure Price Target by Period

	1M	3M	12M
# Anlaysts	1	2	8
Avg Price Target	$30.00	$30.00	$26.81
Last Closing Price	$30.08	$30.08	$30.08
Upside/Downside	-0.27%	-0.27%	-10.87%

In the current month, the average price target of NovoCure stock is $30.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -0.27% decrease as opposed to NovoCure's last price of $30.08. This month's average price target is down 0.00% compared to last quarter, and up 11.90% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 31, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 16, 2024	H.C. Wainwright	Neutral	Buy	Upgrade
Jul 26, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Jul 02, 2024	Piper Sandler	Neutral	Neutral	Hold
Jul 02, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Jun 04, 2024	Wells Fargo	Neutral	Neutral	Hold
May 24, 2024	Piper Sandler	Overweight	Overweight	Hold
May 03, 2024	H.C. Wainwright	Neutral	Neutral	Hold
May 02, 2024	Wells Fargo	Buy	Buy	Hold
May 02, 2024	Evercore ISI	Negative	Negative	Hold
Apr 03, 2024	Wells Fargo	Overweight	Overweight	Hold
Mar 27, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 08, 2023	Piper Sandler	Neutral	Overweight	Upgrade
Jun 07, 2023	Wedbush		Neutral	Upgrade
May 16, 2023	Wells Fargo	Equal-Weight	Overweight	Upgrade
Jan 06, 2023	Piper Sandler	Neutral	Neutral	Hold
Jan 06, 2023	Wells Fargo	Overweight	Equal-Weight	Downgrade
Nov 29, 2022	Wells Fargo		Overweight	Upgrade
Oct 24, 2022	Piper Sandler		Neutral	Downgrade
Feb 08, 2022	Loop Capital Markets		Buy	Initialise

NovoCure's last stock rating was published by H.C. Wainwright on Oct 31, 2024. The company gave NVCR a "Buy" rating, the same as its previous rate.

NovoCure Financial Forecast

NovoCure Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$127.32M	$126.05M	$122.18M	$128.43M	$131.00M	$140.87M	$137.55M	$133.21M	$133.61M	$133.52M	$134.69M	$143.95M	$132.66M	$115.92M	$101.83M	$99.23M	$92.06M
Avg Forecast	$183.72M	$179.53M	$174.33M	$169.29M	$162.58M	$160.13M	$157.27M	$155.16M	$153.05M	$143.95M	$135.83M	$131.44M	$133.80M	$128.75M	$124.25M	$127.77M	$128.40M	$130.61M	$134.97M	$134.08M	$133.00M	$141.27M	$141.50M	$138.70M	$144.00M	$119.51M	$105.70M	$101.92M	$99.20M	$86.94M
High Forecast	$187.87M	$183.57M	$178.26M	$173.10M	$166.25M	$163.74M	$160.82M	$160.34M	$155.90M	$143.99M	$135.83M	$131.44M	$133.85M	$137.79M	$127.05M	$130.65M	$131.29M	$130.61M	$134.97M	$134.08M	$133.00M	$141.27M	$141.50M	$138.70M	$144.00M	$119.51M	$105.70M	$101.92M	$99.20M	$86.94M
Low Forecast	$179.78M	$175.68M	$170.59M	$165.66M	$159.09M	$156.69M	$153.90M	$149.57M	$150.52M	$143.90M	$135.83M	$131.44M	$133.75M	$123.39M	$121.59M	$125.02M	$125.65M	$130.61M	$134.97M	$134.08M	$133.00M	$141.27M	$141.50M	$138.70M	$144.00M	$119.51M	$105.70M	$101.92M	$99.20M	$86.94M
# Analysts	1	1	1	1	1	1	1	2	6	3	1	1	2	6	3	3	4	4	4	4	3	3	3	3	3	16	8	11	7	11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.99%	1.01%	0.96%	1.00%	1.00%	1.04%	1.03%	1.00%	0.95%	0.94%	0.97%	1.00%	1.11%	1.10%	1.00%	1.00%	1.06%

NovoCure's average Quarter revenue forecast for Dec 23 based on 2 analysts is $133.80M, with a low forecast of $133.75M, and a high forecast of $133.85M. NVCR's average Quarter revenue forecast represents a 5.09% increase compared to the company's last Quarter revenue of $127.32M (Sep 23).

NovoCure EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	6	3	1	1	2	6	3	3	4	4	4	4	3	3	3	3	3	16	8	11	7	11
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-55.44M	$-62.66M	$-60.25M	$-42.98M	$-21.95M	$-18.47M	$1.80M	$-22.91M	$-7.80M	$-10.76M	$-364.00K	$11.30M	$13.23M	$6.65M	$-3.92M	$875.00K	$3.23M
Avg Forecast	$-14.78M	$-14.44M	$-14.03M	$-13.62M	$-13.08M	$-12.88M	$-12.65M	$-12.48M	$-12.31M	$-11.58M	$-10.93M	$-2.66M	$-10.76M	$-10.36M	$-10.00M	$-2.41M	$-13.86M	$-14.03M	$-14.50M	$-2.58M	$-14.29M	$-15.18M	$-15.20M	$-1.31M	$-15.47M	$-12.84M	$-11.36M	$-4.32M	$-10.66M	$-9.34M
High Forecast	$-14.46M	$-14.13M	$-13.72M	$-13.33M	$-12.80M	$-12.61M	$-12.38M	$-12.03M	$-12.11M	$-11.58M	$-10.93M	$-2.12M	$-10.76M	$-9.93M	$-9.78M	$-1.93M	$-11.09M	$-14.03M	$-14.50M	$-2.07M	$-14.29M	$-15.18M	$-15.20M	$-1.05M	$-15.47M	$-12.84M	$-11.36M	$-3.45M	$-10.66M	$-9.34M
Low Forecast	$-15.11M	$-14.77M	$-14.34M	$-13.93M	$-13.38M	$-13.17M	$-12.94M	$-12.90M	$-12.54M	$-11.58M	$-10.93M	$-3.19M	$-10.77M	$-11.09M	$-10.22M	$-2.90M	$-16.63M	$-14.03M	$-14.50M	$-3.10M	$-14.29M	$-15.18M	$-15.20M	$-1.57M	$-15.47M	$-12.84M	$-11.36M	$-5.18M	$-10.66M	$-9.34M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	5.35%	6.27%	24.95%	3.10%	1.56%	1.27%	-0.70%	1.60%	0.51%	0.71%	0.28%	-0.73%	-1.03%	-0.59%	0.91%	-0.08%	-0.35%

4 analysts predict NVCR's average Quarter EBITDA for Jun 22 to be $-14.50M, with a high of $-14.50M and a low of $-14.50M. This is -903.89% lower than NovoCure's previous annual EBITDA (Mar 22) of $1.80M.

NovoCure Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	6	3	1	1	2	6	3	3	4	4	4	4	3	3	3	3	3	16	8	11	7	11
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-49.48M	$-57.42M	$-53.06M	$-37.30M	$-26.58M	$-24.01M	$-4.65M	$-26.46M	$-13.12M	$-14.64M	$-4.13M	$4.92M	$9.28M	$1.66M	$3.95M	$4.26M	$1.93M
Avg Forecast	$-34.64M	$-35.72M	$-36.80M	$-40.05M	$-43.66M	$-41.49M	$-41.13M	$-41.49M	$-39.12M	$-36.13M	$-43.61M	$-7.65M	$-56.44M	$-56.83M	$-54.12M	$-6.95M	$-16.01M	$-28.16M	$-15.62M	$-7.44M	$-11.04M	$-7.95M	$943.56K	$-14.86M	$13.52M	$4.19M	$-403.88K	$4.35M	$1.69M	$-4.77M
High Forecast	$-33.67M	$-34.73M	$-35.78M	$-38.93M	$-42.44M	$-40.34M	$-39.99M	$-36.61M	$-32.60M	$-35.13M	$-42.39M	$-6.12M	$-50.05M	$-46.99M	$-52.61M	$-5.56M	$-12.81M	$-28.16M	$-15.62M	$-5.95M	$-11.04M	$-7.95M	$943.56K	$-11.89M	$13.52M	$4.19M	$-403.88K	$5.22M	$1.69M	$-4.77M
Low Forecast	$-35.65M	$-36.77M	$-37.88M	$-41.23M	$-44.94M	$-42.71M	$-42.34M	$-50.04M	$-44.56M	$-37.19M	$-44.89M	$-9.18M	$-64.96M	$-62.29M	$-55.71M	$-8.34M	$-19.21M	$-28.16M	$-15.62M	$-8.92M	$-11.04M	$-7.95M	$943.56K	$-17.83M	$13.52M	$4.19M	$-403.88K	$3.48M	$1.69M	$-4.77M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.87%	1.06%	7.63%	2.33%	0.94%	1.54%	0.63%	2.40%	1.65%	-15.52%	0.28%	0.36%	2.22%	-4.10%	0.91%	2.52%	-0.40%

NovoCure's average Quarter net income forecast for Mar 21 is $-14.86M, with a range of $-17.83M to $-11.89M. NVCR's average Quarter net income forecast represents a -402.23% decrease compared to the company's last Quarter net income of $4.92M (Dec 20).

NovoCure SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	6	3	1	1	2	6	3	3	4	4	4	4	3	3	3	3	3	16	8	11	7	11
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$99.85M	$99.27M	$93.11M	$87.70M	$73.90M	$76.42M	$68.39M	$69.99M	$63.81M	$66.90M	$62.48M	$59.72M	$56.42M	$53.87M	$55.44M	$50.55M	$46.54M
Avg Forecast	$103.27M	$100.91M	$97.99M	$95.16M	$91.39M	$90.01M	$88.41M	$87.22M	$86.03M	$80.91M	$76.35M	$112.55M	$75.21M	$72.37M	$69.84M	$102.31M	$42.35M	$73.42M	$75.87M	$109.43M	$74.76M	$79.41M	$79.54M	$77.97M	$80.94M	$67.18M	$59.41M	$60.99M	$55.76M	$48.87M
High Forecast	$105.60M	$103.19M	$100.20M	$97.30M	$93.45M	$92.04M	$90.40M	$90.13M	$87.63M	$80.94M	$76.35M	$135.06M	$75.24M	$77.45M	$71.42M	$122.78M	$50.81M	$73.42M	$75.87M	$131.31M	$74.76M	$79.41M	$79.54M	$77.97M	$80.94M	$67.18M	$59.41M	$73.18M	$55.76M	$48.87M
Low Forecast	$101.06M	$98.75M	$95.89M	$93.12M	$89.43M	$88.08M	$86.51M	$84.07M	$84.61M	$80.89M	$76.35M	$90.04M	$75.18M	$69.36M	$68.35M	$81.85M	$33.88M	$73.42M	$75.87M	$87.54M	$74.76M	$79.41M	$79.54M	$77.97M	$80.94M	$67.18M	$59.41M	$48.79M	$55.76M	$48.87M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.38%	1.42%	0.91%	2.07%	1.01%	1.01%	0.63%	0.94%	0.80%	0.84%	0.80%	0.74%	0.84%	0.91%	0.91%	0.91%	0.95%

NovoCure's average Quarter SG&A projection for Dec 23 is $75.21M, based on 2 Wall Street analysts, with a range of $75.18M to $75.24M. The forecast indicates a -24.68% fall compared to NVCR last annual SG&A of $99.85M (Sep 23).

NovoCure EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	6	3	1	1	2	6	3	3	4	4	4	4	3	3	3	3	3	16	8	11	7	11
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.46	$-0.54	$-0.50	$-0.36	$-0.25	$-0.23	$-0.04	$-0.25	$-0.13	$-0.14	$-0.04	$0.05	$0.09	$0.02	$0.04	$0.04	$0.02
Avg Forecast	$-0.32	$-0.33	$-0.34	$-0.37	$-0.40	$-0.38	$-0.38	$-0.38	$-0.36	$-0.33	$-0.40	$-0.42	$-0.52	$-0.53	$-0.50	$-0.32	$-0.30	$-0.26	$-0.14	$-0.18	$-0.10	$-0.07	$0.01	$0.01	$0.13	$0.04	$-0.00	$0.03	$0.02	$-0.04
High Forecast	$-0.31	$-0.32	$-0.33	$-0.36	$-0.39	$-0.37	$-0.37	$-0.34	$-0.30	$-0.32	$-0.39	$-0.41	$-0.46	$-0.43	$-0.49	$-0.31	$-0.29	$-0.26	$-0.14	$-0.18	$-0.10	$-0.07	$0.01	$0.01	$0.13	$0.04	$-0.00	$0.03	$0.02	$-0.04
Low Forecast	$-0.33	$-0.34	$-0.35	$-0.38	$-0.42	$-0.39	$-0.39	$-0.46	$-0.41	$-0.34	$-0.41	$-0.43	$-0.60	$-0.58	$-0.51	$-0.33	$-0.31	$-0.26	$-0.14	$-0.18	$-0.10	$-0.07	$0.01	$0.01	$0.13	$0.04	$-0.00	$0.03	$0.02	$-0.04
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.88%	1.08%	1.55%	1.19%	0.96%	1.59%	0.24%	2.44%	1.76%	-15.98%	-2.67%	0.40%	2.31%	-5.33%	1.17%	2.55%	-0.45%

According to 3 Wall Street analysts, NovoCure's projected average Quarter EPS for Mar 21 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -70.00% decrease compared to NVCR previous annual EPS of $0.05 (Dec 20).

NovoCure Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
TMDX	TransMedics Group	$59.28	$116.33	96.24%	Buy
LIVN	LivaNova	$45.70	$68.25	49.34%	Buy
CNMD	CONMED	$69.14	$97.00	40.30%	Buy
INMD	InMode	$16.63	$21.75	30.79%	Hold
IRTC	iRhythm	$86.92	$110.86	27.54%	Buy
INSP	Inspire Medical Systems	$184.65	$233.80	26.62%	Buy
NARI	Inari Medical	$51.93	$65.63	26.38%	Buy
ITGR	Integer	$133.58	$153.50	14.91%	Buy
MASI	Masimo	$168.59	$183.33	8.74%	Buy
GMED	Globus Medical	$82.67	$85.00	2.82%	Buy
PODD	Insulet	$263.36	$268.00	1.76%	Buy
NVCR	NovoCure	$30.08	$30.00	-0.27%	Hold
PEN	Penumbra	$238.18	$230.25	-3.33%	Buy

NVCR Forecast FAQ

Is NovoCure a good buy?

No, according to 6 Wall Street analysts, NovoCure (NVCR) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of NVCR's total ratings.

What is NVCR's price target?

NovoCure (NVCR) average price target is $30 with a range of $30 to $30, implying a -0.27% from its last price of $30.08. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will NovoCure stock go up soon?

According to Wall Street analysts' prediction for NVCR stock, the company can go down by -0.27% (from the last price of $30.08 to the average price target of $30), down by -0.27% based on the highest stock price target, and down by -0.27% based on the lowest stock price target.

Can NovoCure stock reach $50?

NVCR's average twelve months analyst stock price target of $30 does not support the claim that NovoCure can reach $50 in the near future.

What is NovoCure's current price target trend?

1 Wall Street analyst forecast a $30 price target for NovoCure (NVCR) this month, down -0.27% from its last price of $30.08. Compared to the last 3 and 12 months, the average price target decreased by -0.27% and decreased by -10.87%, respectively.

What are NovoCure's analysts' financial forecasts?

NovoCure's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $635.14M (high $651.14M, low $619.26M), average EBITDA is $-51.1M (high $-49.822M, low $-52.387M), average net income is $-168M (high $-159M, low $-180M), average SG&A $357.02M (high $366.02M, low $348.09M), and average EPS is $-1.55 (high $-1.472, low $-1.663). NVCR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $706.87M (high $722.8M, low $691.7M), average EBITDA is $-56.87M (high $-55.651M, low $-58.153M), average net income is $-147M (high $-143M, low $-152M), average SG&A $397.34M (high $406.3M, low $388.82M), and average EPS is $-1.36 (high $-1.322, low $-1.4).

Did the NVCR's actual financial results beat the analysts' financial forecasts?

Based on NovoCure's last annual report (Dec 2022), the company's revenue was $537.84M, beating the average analysts forecast of $528.05M by 1.85%. Apple's EBITDA was $-89.523M, beating the average prediction of $-44.977M by 99.04%. The company's net income was $-92.534M, beating the average estimation of $-67.215M by 37.67%. Apple's SG&A was $306.41M, beating the average forecast of $301.06M by 1.78%. Lastly, the company's EPS was $-0.88, missing the average prediction of $-0.894 by -1.56%. In terms of the last quarterly report (Sep 2023), NovoCure's revenue was $127.32M, missing the average analysts' forecast of $128.75M by -1.11%. The company's EBITDA was $-55.442M, beating the average prediction of $-10.358M by 435.23%. NovoCure's net income was $-49.485M, missing the average estimation of $-56.83M by -12.92%. The company's SG&A was $99.85M, beating the average forecast of $72.37M by 37.97%. Lastly, the company's EPS was $-0.46, missing the average prediction of $-0.525 by -12.38%